Molecular Profiling of Druggable Targets in Clear Cell Renal Cell Carcinoma Through Targeted RNA Sequencing
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular Profiling of Druggable Targets in Clear Cell Renal Cell Carcinoma Through Targeted RNA Sequencing
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-03-01
DOI
10.3389/fonc.2019.00117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal
- (2018) Samra Turajlic et al. CELL
- PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
- (2018) Otto Kauko et al. Science Translational Medicine
- Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes
- (2018) Corina N. A. M. van den Heuvel et al. Scientific Reports
- Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity
- (2017) Corina N.A.M. van den Heuvel et al. MOLECULAR CANCER RESEARCH
- Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma
- (2017) Billy Amzal et al. PLoS One
- Quantification of differential gene expression by multiplexed targeted resequencing of cDNA
- (2017) Peer Arts et al. Nature Communications
- Profiling of the metabolic transcriptome via single molecule molecular inversion probes
- (2017) Tessa de Bitter et al. Scientific Reports
- Von Hippel–Lindau disease: a single gene, several hereditary tumors
- (2017) J. Crespigio et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) B. Escudier et al. ANNALS OF ONCOLOGY
- An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
- (2016) A. Ari Hakimi et al. CANCER CELL
- The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer
- (2016) Lan-Ying Gou et al. Oncotarget
- Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein
- (2015) Anna C. Navis et al. ACTA NEUROPATHOLOGICA
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism
- (2015) Emelyn H. Shroff et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma
- (2015) Giuseppe Lucarelli et al. Oncotarget
- Suppression of PGC-1α Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma
- (2015) Edward L. LaGory et al. Cell Reports
- MIPgen: optimized modeling and design of molecular inversion probes for targeted resequencing
- (2014) Evan A. Boyle et al. BIOINFORMATICS
- Fructose-1,6-bisphosphatase opposes renal carcinoma progression
- (2014) Bo Li et al. NATURE
- FBP1 depletion feeds ccRCC
- (2014) Robert Phillips Nature Reviews Urology
- Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma
- (2014) Francesco Gatto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms of resistance to EGFR targeted therapies
- (2013) Gorjan Hrustanovic et al. CANCER BIOLOGY & THERAPY
- In Vivo HIF-Mediated Reductive Carboxylation Is Regulated by Citrate Levels and Sensitizes VHL-Deficient Cells to Glutamine Deprivation
- (2013) Paulo A. Gameiro et al. Cell Metabolism
- Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials
- (2013) A.M. Molina et al. EUROPEAN JOURNAL OF CANCER
- Integrated molecular analysis of clear-cell renal cell carcinoma
- (2013) Yusuke Sato et al. NATURE GENETICS
- Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2
- (2013) Anna C. Navis et al. PLoS One
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2013) Alberto Bardelli et al. Cancer Discovery
- c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
- (2012) G. T. Gibney et al. ANNALS OF ONCOLOGY
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation
- (2012) L E Moore et al. Oncogenesis
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence
- (2011) T. E. Hutson ONCOLOGIST
- Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors
- (2011) Lee E. Moore et al. PLoS Genetics
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition
- (2010) Simona Corso et al. Molecular Cancer
- Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors
- (2009) Alessandro A. Boezio et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
- (2009) Michalis V Karamouzis et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search